San Diego’s Histogen, a regenerative medicine company with technology for using nascent skin cells to produce “cosmeceutical” products, says the FDA has given a green light to its application for an initial safety study of its hair stimulation product in women.... Read more »
Most wedding registries are focused on the lead-up to the day of the ceremony. New York startup Zola also sees opportunity in connecting with—and making a sales pitch to—married couples years after they’ve tied the knot.
Zola is an “e-commerce business... Read more »
Here’s a case study of how fast things can change in biopharma. For a few years, a type of cancer drug called an IDO inhibitor was all the rage, a promising path to expanding the reach of immunotherapy. Major drug makers... Read more »
In the five years since it was founded, San Diego-based Arcturus Therapeutics (NASDAQ: ARCT) says it has built a versatile platform for developing a variety of RNA-based medicines. On the Arcturus website, the company’s pre-clinical development pipeline includes drugs for... Read more »
If you’ve already liberated yourself from a cable subscription in favor of streaming video services over the Internet, you’re parcelling out your dollars to get the content you want most from services such as Netflix, Hulu, and N.B.A. League Pass.
A... Read more »
California employers who classify their workers as independent contractors will be consulting their lawyers today, says A. Mark Pope, an attorney who helped persuade the state’s highest court to establish sweeping new restrictions on hiring so-called “gig workers.”
The California Supreme... Read more »
Sales of weight loss drugs have been light, and the Vivus drug Qsymia is no exception. Facing declining revenue as well as a looming mountain of debt, Vivus has been casting about for a new strategy. It looks like it’s found... Read more »
In cities across the United States, the benefits of bike-sharing and electric scooters that can be easily rented with a smartphone app have often been overshadowed by controversy.
In Dallas, Los Angeles, and Washington, DC, for example, complaints... Read more »
After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs, San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of interleukin-2, an anti-cancer drug of intense commercial interest in the 1980s.... Read more »